Aptorum Group Ltd
Company Information
Industry Measuring & Controlling Devices, NEC
SIC Code 3829
Entity Type other
SEC Category Non-accelerated filer
State of Incorporation Cayman Islands
Business Address 17 HANOVER SQUARE, LONDON, X0, W1S 1BN
Mailing Address 17 HANOVER SQUARE, LONDON, X0, W1S 1BN
Phone 852 3953 7700
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025 FY
$431K
Revenue
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 11, 2026 | View on SEC |
| 6-K Foreign company current report | March 6, 2026 | View on SEC |
| 6-K Foreign company current report | February 6, 2026 | View on SEC |
| 6-K Foreign company current report | January 22, 2026 | View on SEC |
| 424B5 Prospectus supplement | December 5, 2025 | View on SEC |
| F-1 Foreign company IPO registration | November 17, 2025 | View on SEC |
| 6-K Foreign company current report | October 16, 2025 | View on SEC |
| 6-K Foreign company current report | October 15, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 14, 2025 | View on SEC |
Annual Reports
20-F March 27, 2026
- Strategic merger with DiamiR Biosciences to enter the high-growth microRNA diagnostics market.
- Lead drug candidate SACT-1 has received Orphan Drug Designation from the FDA.
Related Companies
Companies in the same industry (SIC: 3829)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.